PI Industries Ltd
Q1 FY27, unaudited
- Revenue
- ₹1,598.90 Cr
- Profit after tax
- ₹341.50 Cr
As filed with the exchange, standalone basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 1,598.90 | −9.62% | 6,182.70 |
| Other income | 60.80 | −24.00% | 307.70 |
| Total income | 1,659.70 | −10.24% | 6,490.40 |
| Employee benefit expense | 175.40 | +6.50% | 623.80 |
| Finance costs | 2.30 | +43.75% | 7.40 |
| Depreciation & amortisation | 80.30 | +13.74% | 304.60 |
| Total expenses | 1,222.70 | −3.54% | 4,559.20 |
| Profit before tax | 437.00 | −24.85% | 1,798.90 |
| Tax expense | 95.50 | −18.52% | 364.10 |
| Profit after tax | 341.50 | −26.45% | 1,434.80 |
| Total comprehensive income | 379.60 | −19.23% | 1,293.50 |
| Earnings per share, basic | ₹22.50 | ₹94.57 |
|---|---|---|
| Earnings per share, diluted | ₹22.50 | ₹94.56 |
Earnings call
Q4 FY26PI Industries reported consolidated FY26 revenue of Rs 67,137 million with EBITDA margins of 25% and a cash balance of Rs 34,265 million, while Q4 FY26 revenue was Rs 15,652 million, showing sequential growth. Management said the pharma business grew 40% for the full year and that new products contributed 18% of AgChem exports, while domestic agrochemical demand remained impacted by channel inventory, pricing pressure and lower crop acreages. Management said it expects growth in FY27 supported by export recovery, new product launches including the NCE Pioxaniliprole, and continued scale-up of pharma and biologicals.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Filings
12 shown · 66 published by the exchange
19 Aug 2026
ConcallAnalyst / Investor Meet - Intimation
Appears 3 times in the recent filings shown; listed once.
18 Aug 2026
Transcript14 Aug 2026
14 Aug 2026
13 Aug 2026
ConcallAnalyst / Investor Meet - Intimation
Appears 2 times in the recent filings shown; listed once.
13 Aug 2026
Filing12 Aug 2026
12 Aug 2026
11 Aug 2026
Presentation11 Aug 2026
Filing11 Aug 2026
11 Aug 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 19 Aug 2026.